• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

福尔马林固定可提高非小细胞肺癌患者细胞学和组织学标本中程序性死亡配体 1 免疫染色的一致性。

Formalin fixation for optimal concordance of programmed death-ligand 1 immunostaining between cytologic and histologic specimens from patients with non-small cell lung cancer.

机构信息

Department of Pathology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.

Department of Pathology, Isala Hospitals, Zwolle, the Netherlands.

出版信息

Cancer Cytopathol. 2021 Apr;129(4):304-317. doi: 10.1002/cncy.22383. Epub 2020 Oct 27.

DOI:10.1002/cncy.22383
PMID:33108706
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8246726/
Abstract

BACKGROUND

Immunohistochemical staining of programmed death-ligand 1 (PD-L1) is used to determine which patients with non-small cell lung cancer (NSCLC) may benefit most from immunotherapy. Therapeutic management of many patients with NSCLC is based on cytology instead of histology. In this study, concordance of PD-L1 immunostaining between cytology cell blocks and their histologic counterparts was analyzed. Furthermore, the effect of various fixatives and fixation times on PD-L1 immunoreactivity was studied.

METHODS

Paired histologic and cytologic samples from 67 patients with NSCLC were collected by performing fine-needle aspiration on pneumonectomy/lobectomy specimens. Formalin-fixed, agar-based or CytoLyt/PreservCyt-fixed Cellient cell blocks were prepared. Sections from cell blocks and tissue blocks were stained with SP263 (standardized assay) and 22C3 (laboratory-developed test) antibodies. PD-L1 scores were compared between histology and cytology. In addition, immunostaining was compared between PD-L1-expressing human cell lines fixed in various fixatives at increasing increments in fixation duration.

RESULTS

Agar cell blocks and tissue blocks showed substantial agreement (κ = 0.70 and κ = 0.67, respectively), whereas fair-to-moderate agreement was found between Cellient cell blocks and histology (κ = 0.28 and κ = 0.49, respectively). Cell lines fixed in various alcohol-based fixatives showed less PD-L1 immunoreactivity compared with those fixed in formalin. In contrast to SP263, additional formalin fixation after alcohol fixation resulted in preserved staining intensity using the 22C3 laboratory-developed test and the 22C3 pharmDx assay.

CONCLUSIONS

Performing PD-L1 staining on cytologic specimens fixed in alcohol-based fixatives could result in false-negative immunostaining results, whereas fixation in formalin leads to higher and more histology-concordant PD-L1 immunostaining. The deleterious effect of alcohol fixation could be reversed to some degree by postfixation in formalin.

摘要

背景

程序性死亡配体 1(PD-L1)的免疫组化染色用于确定哪些非小细胞肺癌(NSCLC)患者最有可能从免疫治疗中获益。许多 NSCLC 患者的治疗管理基于细胞学而不是组织学。在这项研究中,分析了细胞学细胞块与组织学对应物之间 PD-L1 免疫染色的一致性。此外,还研究了各种固定剂和固定时间对 PD-L1 免疫反应性的影响。

方法

通过对肺切除术/肺叶切除术标本进行细针穿刺,收集了 67 例 NSCLC 患者的配对组织学和细胞学样本。使用福尔马林固定、琼脂基或 CytoLyt/PreservCyt 固定的 Cellient 细胞块制备。从细胞块和组织块的切片用 SP263(标准化检测)和 22C3(实验室开发的检测)抗体染色。比较组织学和细胞学之间的 PD-L1 评分。此外,还比较了在不同固定剂中固定时间逐渐增加的情况下,表达 PD-L1 的人细胞系的免疫染色。

结果

琼脂细胞块和组织块显示出实质性的一致性(κ=0.70 和 κ=0.67),而 Cellient 细胞块与组织学之间则存在适度至良好的一致性(κ=0.28 和 κ=0.49)。与福尔马林相比,用各种醇基固定剂固定的细胞系显示出较低的 PD-L1 免疫反应性。与 SP263 不同,在用醇固定后再用福尔马林固定,使用 22C3 实验室开发的检测和 22C3 pharmDx 检测可保留更高和更与组织学一致的染色强度。

结论

在醇基固定剂固定的细胞学标本上进行 PD-L1 染色可能导致免疫染色结果为假阴性,而福尔马林固定则导致更高和更与组织学一致的 PD-L1 免疫染色。通过在福尔马林后再次固定,可以在一定程度上逆转醇固定的有害影响。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a7ea/8246726/4ca3155a530c/CNCY-129-304-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a7ea/8246726/687f8e3842b6/CNCY-129-304-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a7ea/8246726/8d867be0a42c/CNCY-129-304-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a7ea/8246726/bd769d6e5b0d/CNCY-129-304-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a7ea/8246726/4ed78bbc1ad0/CNCY-129-304-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a7ea/8246726/72aa4cabe8b0/CNCY-129-304-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a7ea/8246726/4ca3155a530c/CNCY-129-304-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a7ea/8246726/687f8e3842b6/CNCY-129-304-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a7ea/8246726/8d867be0a42c/CNCY-129-304-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a7ea/8246726/bd769d6e5b0d/CNCY-129-304-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a7ea/8246726/4ed78bbc1ad0/CNCY-129-304-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a7ea/8246726/72aa4cabe8b0/CNCY-129-304-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a7ea/8246726/4ca3155a530c/CNCY-129-304-g001.jpg

相似文献

1
Formalin fixation for optimal concordance of programmed death-ligand 1 immunostaining between cytologic and histologic specimens from patients with non-small cell lung cancer.福尔马林固定可提高非小细胞肺癌患者细胞学和组织学标本中程序性死亡配体 1 免疫染色的一致性。
Cancer Cytopathol. 2021 Apr;129(4):304-317. doi: 10.1002/cncy.22383. Epub 2020 Oct 27.
2
False-negative programmed death-ligand 1 immunostaining in ethanol-fixed endobronchial ultrasound-guided transbronchial needle aspiration specimens of non-small-cell lung cancer patients.非小细胞肺癌患者经支气管超声引导针吸活检标本中乙醇固定导致程序性死亡配体 1 免疫染色假阴性。
Histopathology. 2021 Oct;79(4):480-490. doi: 10.1111/his.14373. Epub 2021 Jun 8.
3
Programmed death-ligand 1 expression on direct Pap-stained cytology smears from non-small cell lung cancer: Comparison with cell blocks and surgical resection specimens.程序性死亡配体 1 在非小细胞肺癌直接巴氏染色细胞学涂片上的表达:与细胞块和手术切除标本的比较。
Cancer Cytopathol. 2019 Jul;127(7):470-480. doi: 10.1002/cncy.22155. Epub 2019 Jun 27.
4
Programmed death ligand 1 testing in non-small cell lung carcinoma cytology cell block and aspirate smear preparations.程序性死亡配体 1 检测在非小细胞肺癌细胞学细胞块和抽吸涂片制备中的应用。
Cancer Cytopathol. 2018 May;126(5):342-352. doi: 10.1002/cncy.21987. Epub 2018 Mar 2.
5
Comparative analysis of programmed death ligand 1 expression in paired cytologic and histologic specimens of non-small cell lung cancer.非小细胞肺癌配对细胞学和组织学标本中程序性死亡配体 1 表达的对比分析。
Cancer Cytopathol. 2020 Aug;128(8):580-588. doi: 10.1002/cncy.22292. Epub 2020 May 28.
6
Performance of Ventana SP263 PD-L1 assay in endobronchial ultrasound guided-fine-needle aspiration derived non-small-cell lung carcinoma samples.SP263 PD-L1 检测试剂盒在经支气管超声引导下细针抽吸术获取的非小细胞肺癌样本中的性能。
Diagn Cytopathol. 2021 Mar;49(3):355-362. doi: 10.1002/dc.24654. Epub 2020 Nov 3.
7
Characterization of PD-L1 Immunohistochemical Expression in Cell Blocks With Different Specimen Fixation and Processing Methods.不同标本固定和处理方法的细胞块中程序性死亡配体1免疫组化表达的特征分析
Appl Immunohistochem Mol Morphol. 2019 Feb;27(2):107-113. doi: 10.1097/PAI.0000000000000572.
8
Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma.一种经验证可用于分析非小细胞肺癌和头颈部鳞状细胞癌的程序性细胞死亡配体-1免疫组织化学检测方法的开发。
Diagn Pathol. 2016 Oct 8;11(1):95. doi: 10.1186/s13000-016-0545-8.
9
Comparison of PD-L1 Expression Using 2 Validated PD-L1 IHC 22C3 pharmDx Methods in Non-Small Cell Lung Cancer in a Routine Hospital Setting.在常规医院环境中使用两种经过验证的 PD-L1 IHC 22C3 pharmDx 方法检测非小细胞肺癌中的 PD-L1 表达的比较。
Appl Immunohistochem Mol Morphol. 2021 Jan;29(1):49-55. doi: 10.1097/PAI.0000000000000827.
10
Use of the 22C3 anti-programmed death-ligand 1 antibody to determine programmed death-ligand 1 expression in cytology samples obtained from non-small cell lung cancer patients.利用 22C3 抗程序性死亡配体 1 抗体检测非小细胞肺癌患者细胞学样本中的程序性死亡配体 1 表达。
Cancer Cytopathol. 2018 Apr;126(4):264-274. doi: 10.1002/cncy.21977. Epub 2018 Feb 7.

引用本文的文献

1
Development of a Novel Peptide with RGD Tumor Homing Motif: Evaluation of its Anticancer Potential in Hepatocellular Carcinoma and Colon Cancer Cells.一种具有RGD肿瘤归巢基序的新型肽的研发:评估其在肝癌和结肠癌细胞中的抗癌潜力
Recent Pat Biotechnol. 2025;19(2):128-141. doi: 10.2174/0118722083300452240315035722.
2
Why PD-L1 expression varies between studies of lung cancer: results from a Bayesian meta-analysis.肺癌研究中PD-L1表达为何在不同研究间存在差异:贝叶斯荟萃分析结果
Sci Rep. 2025 Feb 4;15(1):4166. doi: 10.1038/s41598-024-80301-9.
3
Diagnostic and Predictive Immunocytochemistry in Lung Cancer.

本文引用的文献

1
Programmed death ligand 1 expression in EBUS aspirates of non-small cell lung cancer: Is interpretation affected by type of fixation?程序性死亡配体 1 在非小细胞肺癌 EBUS 抽吸物中的表达:固定类型是否会影响其解释?
Cancer Cytopathol. 2020 Feb;128(2):100-106. doi: 10.1002/cncy.22216. Epub 2019 Dec 18.
2
Mapping the binding sites of antibodies utilized in programmed cell death ligand-1 predictive immunohistochemical assays for use with immuno-oncology therapies.绘制用于免疫肿瘤治疗的程序性细胞死亡配体-1 预测性免疫组织化学检测中使用的抗体结合位点图谱。
Mod Pathol. 2020 Apr;33(4):518-530. doi: 10.1038/s41379-019-0372-z. Epub 2019 Sep 26.
3
肺癌的诊断与预测性免疫细胞化学
Acta Cytol. 2025;69(1):69-76. doi: 10.1159/000541478. Epub 2024 Sep 19.
4
Evaluation of a Novel Fixative Solution for Liquid-Based Cytology in Diagnostic Cytopathology.用于诊断细胞病理学中液基细胞学的新型固定液的评估
Diagnostics (Basel). 2023 Dec 5;13(24):3601. doi: 10.3390/diagnostics13243601.
5
Assessing PD-L1 Expression in Head and Neck Squamous Cell Carcinoma: Trials and Tribulations.评估头颈部鳞状细胞癌中的 PD-L1 表达:挑战与困境。
Head Neck Pathol. 2023 Dec;17(4):969-975. doi: 10.1007/s12105-023-01590-6. Epub 2023 Nov 6.
6
Comparative evaluation of PD-L1 expression in cytology imprints, circulating tumour cells and tumour tissue in non-small cell lung cancer patients.比较细胞学印片、循环肿瘤细胞与非小细胞肺癌患者肿瘤组织中 PD-L1 表达的评估。
Mol Oncol. 2023 May;17(5):737-746. doi: 10.1002/1878-0261.13415. Epub 2023 Mar 23.
7
Nationwide differences in cytology fixation and processing methods and their impact on interlaboratory variation in PD-L1 positivity.细胞学固定和处理方法的全国性差异及其对 PD-L1 阳性率的实验室间差异的影响。
Virchows Arch. 2023 Apr;482(4):707-720. doi: 10.1007/s00428-022-03446-w. Epub 2022 Nov 12.
8
Program death ligand-1 immunocytochemistry in lung cancer cytological samples: A systematic review.程序性死亡配体-1 免疫细胞化学在肺癌细胞学样本中的应用:系统评价。
Diagn Cytopathol. 2022 Jun;50(6):313-323. doi: 10.1002/dc.24955. Epub 2022 Mar 16.
9
PD-L1 Expression in Non-Small Cell Lung Cancer: Data from a Referral Center in Spain.非小细胞肺癌中PD-L1的表达:来自西班牙一家转诊中心的数据。
Diagnostics (Basel). 2021 Aug 11;11(8):1452. doi: 10.3390/diagnostics11081452.
10
PD-L1 Testing in Cytological Non-Small Cell Lung Cancer Specimens: A Comparison with Biopsies and Review of the Literature.细胞非小细胞肺癌标本中 PD-L1 的检测:与活检的比较和文献复习。
Acta Cytol. 2021;65(6):501-509. doi: 10.1159/000517078. Epub 2021 Jul 7.
CytoLyt fixation significantly inhibits MIB1 immunoreactivity whereas alternative Ki-67 clone 30-9 is not susceptible to the inhibition: Critical diagnostic implications.
Cytolyt 固定显著抑制 MIB1 免疫反应性,而替代的 Ki-67 克隆 30-9 则不易受到抑制:具有重要的诊断意义。
Cancer Cytopathol. 2019 Oct;127(10):643-649. doi: 10.1002/cncy.22170. Epub 2019 Aug 9.
4
Removal of N-Linked Glycosylation Enhances PD-L1 Detection and Predicts Anti-PD-1/PD-L1 Therapeutic Efficacy.去除 N-连接糖基化可增强 PD-L1 的检测,并预测抗 PD-1/PD-L1 治疗效果。
Cancer Cell. 2019 Aug 12;36(2):168-178.e4. doi: 10.1016/j.ccell.2019.06.008. Epub 2019 Jul 18.
5
Assessment of Programmed Death-Ligand 1 (PD-L1) Immunohistochemical Expression on Cytology Specimens in Non-Small Cell Lung Carcinoma.非小细胞肺癌细胞学标本中程序性死亡配体 1(PD-L1)免疫组织化学表达的评估。
Am J Clin Pathol. 2019 Mar 1;151(4):403-415. doi: 10.1093/ajcp/aqy164.
6
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.转移性非小细胞肺癌:欧洲肿瘤内科学会临床实践诊断、治疗及随访指南
Ann Oncol. 2018 Oct 1;29(Suppl 4):iv192-iv237. doi: 10.1093/annonc/mdy275.
7
Cell blocks in cytopathology: An update.细胞病理学中的细胞块:最新进展。
Cytopathology. 2018 Dec;29(6):505-524. doi: 10.1111/cyt.12627. Epub 2018 Sep 27.
8
PD-L1 immunohistochemistry in patients with non-small cell lung cancer.非小细胞肺癌患者的程序性死亡受体配体1免疫组织化学检测
J Thorac Dis. 2018 Jul;10(Suppl 18):S2127-S2129. doi: 10.21037/jtd.2018.06.30.
9
Essential preanalytics in PD-L1 immunocytochemistry.PD-L1免疫细胞化学中的基本分析前事项。
Histopathology. 2019 Jan;74(2):362-364. doi: 10.1111/his.13717. Epub 2018 Oct 23.
10
PD-L1 testing using the clone 22C3 pharmDx kit for selection of patients with non-small cell lung cancer to receive immune checkpoint inhibitor therapy: are cytology cell blocks a viable option?使用克隆22C3免疫组化检测试剂盒进行程序性死亡受体配体1(PD-L1)检测以选择接受免疫检查点抑制剂治疗的非小细胞肺癌患者:细胞学细胞块是一个可行的选择吗?
J Am Soc Cytopathol. 2018 May-Jun;7(3):133-141. doi: 10.1016/j.jasc.2018.02.003. Epub 2018 Feb 16.